Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells

Molecular and Cellular Endocrinology

Volumn 296, Issue 1-2, 2008, Pages 1-9

  Sheng, Shubin ^a   Barnett, Daniel H ^a   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Breast cancer; Estradiol; Estrogen receptor; Gene expression; SERM; Tamoxifen

Indexed keywords

CYTOKERATIN 13; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HISTONE; RALOXIFENE; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; BREAST CANCER; CONTROLLED STUDY; DRUG MECHANISM; GENE ACTIVITY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING;

BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-13; LIGANDS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 56049100223     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.09.022     Document Type: Article

References (41)

1. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
2. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., Fox E.A., Silver P.A., and Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
3. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., Brodsky A.S., Keeton E.K., Fertuck K.C., Hall G.F., Wang Q., Bekiranov S., Sementchenko V., Fox E.A., Silver P.A., Gingeras T.R., Liu X.S., and Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38 (2006) 1289-1297
4. Choi I., Gudas L.J., and Katzenellenbogen B.S. Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. Mol. Cell. Endocrinol. 164 (2000) 225-237
5. Chu Y.W., Runyan R.B., Oshima R.G., and Hendrix M.J. Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4261-4265
6. Chu Y.W., Seftor E.A., Romer L.H., and Hendrix M.J. Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am. J. Pathol. 148 (1996) 63-69
7. Deroo B.J., and Korach K.S. Estrogen receptors and human disease. J. Clin. Invest. 116 (2006) 561-570
8. Eeckhoute J., Carroll J.S., Geistlinger T.R., Torres-Arzayus M.I., and Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 20 (2006) 2513-2526
9. Fan M., Nakshatri H., and Nephew K.P. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol. Endocrinol. 18 (2004) 2603-2615
10. Frasor J., Chang E.C., Komm B., Lin C.Y., Vega V.B., Liu E.T., Miller L.D., Smeds J., Bergh J., and Katzenellenbogen B.S. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 66 (2006) 7334-7340
11. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
12. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64 (2004) 1522-1533
13. Green K.A., and Carroll J.S. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat. Rev. Cancer 7 (2007) 713-722
14. Hendrix M.J., Seftor E.A., Chu Y.W., Trevor K.T., and Seftor R.E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 15 (1996) 507-525
15. Hendrix M.J., Seftor E.A., Seftor R.E., and Trevor K.T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol. 150 (1997) 483-495
16. Hesse M., Magin T.M., and Weber K. Genes for intermediate filament proteins and the draft sequence of the human genome: novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18. J. Cell Sci. 114 (2001) 2569-2575
17. Katzenellenbogen B.S., and Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 31 (2004) 28-38
18. Katzenellenbogen B.S., and Katzenellenbogen J.A. Biomedicine. Defining the "S" in SERMs. Science 295 (2002) 2380-2381
19. Kumar V., and Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156
20. Leu Y.-W., Yan P.S., Fan M., Jin V.X., Liu J.C., Curran E.M., Welshons W.V., Wei S.H., Davuluri R.V., Plass C., Nephew K.P., and Huang T.H.M. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 64 (2004) 8184-8192
21. Lonard D.M., Lanz R.B., and O'malley B.W. Nuclear receptor coregulators and human disease. Endocr. Rev. 28 (2007) 575-587
22. Lonard D.M., Nawaz Z., Smith C.L., and O'malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell 5 (2000) 939-948
23. Lonard D.M., Tsai S.Y., and O'malley B.W. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol. Cell. Biol. 24 (2004) 14-24
24. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., Carroll J.S., Liu X.S., and Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132 (2008) 958-970
25. Magin T.M., Vijayaraj P., and Leube R.E. Structural and regulatory functions of keratins. Exp. Cell Res. 313 (2007) 2021-2032
26. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
27. Murdoch F.E., and Gorski J. The role of ligand in estrogen receptor regulation of gene expression. Mol. Cell. Endocrinol. 78 (1991) C103-C108
28. Olson G.E., Winfrey V.P., Blaeuer G.L., Palisano J.R., and Nagdas S.K. Stage-specific expression of the intermediate filament protein cytokeratin 13 in luminal epithelial cells of secretory phase human endometrium and peri-implantation stage rabbit endometrium. Biol. Reprod. 66 (2002) 1006-1015
29. Rae J.M., Johnson M.D., Scheys J.O., Cordero K.E., Larios J.M., and Lippman M.E. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res. Treat. 92 (2005) 141-149
30. Rivera J.A., Alturaihi H., and Kumar U. Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J. Carcinog. 4 (2005) 10
31. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
32. Shang Y., Hu X., Direnzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
33. Shao W., Keeton E.K., Mcdonnell D.P., and Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11599-11604
34. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
35. Smith R.E., and Good B.C. Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr. Relat. Cancer 10 (2003) 347-357
36. Stender J.D., Frasor J., Komm B., Chang K.C., Kraus W.L., and Katzenellenbogen B.S. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol. Endocrinol. 21 (2007) 2112-2123
37. Strassmer-Weippl K., and Goss P.E. Prevention of breast cancer using SERMs and aromatase inhibitors. J. Mammary Gland Biol. Neoplasia 8 (2003) 5-18
38. Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C., and Yamamoto K.R. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15603-15608
39. Waseem A., Alam Y., Dogan B., White K.N., Leigh I.M., and Waseem N.H. Isolation, sequence and expression of the gene encoding human keratin 13. Gene 215 (1998) 269-279
40. Wijayaratne A.L., and Mcdonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276 (2001) 35684-35692
41. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., and Mcdonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140 (1999) 5828-5840